feedback and remind interested readers that FDA published its 60-day notice in compliance with requirements of the PRA, as administered by OMB, and uses the notice as way to help us with the ongoing evaluation of our existing collection inventory. Toward that end, we have updated explanatory text that accompanies our burden estimate figures. At the same time, we have made no adjustments to our estimated annualized burden.

With regard to comments pertaining to certain AER follow-up information, it is our understanding that provision in 5 CFR 1320.3(h)(5) excepts this collection activity from what an Agency must consider in its calculation of burden to respondents. For the benefit of our stakeholders, however, we note that the majority of burden attributable to information collection activities associated with AER and FDA's MedWatch program is currently approved in OMB control number 0910–0291. Also, other postmarketing AER information collection activity for drugs is accounted for in OMB control number 0910–0230. We have therefore confined our calculation of burden for this information collection to those activities we believe may be attributable to tasks recommended in specific FDA guidance. Established in 2015 to account for burden associated with guidance pertaining to AER for certain facilities as referenced above in this notice, the information collection has evolved to include burden that may be attributable to FDA guidance pertaining to the electronic submission of information, previously approved and included in OMB control number 0910–0827.

Relatedly, we note three other currently approved information collections that account for burden attributable to statutory requirements in sections 503A and 503B: (1) OMB control number 0910–0776, *Registration of Human Drug Compounding Outsourcing Facilities under section 503B of the FFDCA and Associated fees under section 744K,* established in 2014 to account for burden that may be attributable to FDA guidance discussing applicable fees; (2) OMB control number 0910–0858, *Human Drug Compounding, Repackaging, and Related Activities Regarding Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act,* established in 2018 to account for burden that may be attributable to FDA guidance discussing various respective compounding activities; and (3) OMB control number 0910–0883, *Obtaining Information to Understand and Challenges and Opportunities Encountered by Compounding Outsourcing Facilities,* established in 2020 to account for burden that may be attributable to FDA efforts undertaken to help inform us how best to utilize our limited resources toward ensuring the safety of human drug compounding. We note, also, comment on the latter collection, currently pending OMB review and approval under the PRA.

With regard to comments on burden estimates associated with States entering into memoranda of understanding with the Secretary, as described in section 503A(b)(3) of the FD&C Act, we again remind readers our 60-day notice was published in compliance with requirements of the PRA. Acknowledging no current activity in this regard, the figure of ''1'' is proffered in accordance with FDA's understanding of requirements in 5 CFR 1320.5(a), as a minimum placeholder for potential activity and in acknowledgement of any burden associated with informal inquiry, as described in 5 CFR 1320.3(b)(1)(5).

With regard to comments pertaining to the accuracy of FDA's estimate of both the number of respondents and amount of effort for requisite tasks, we appreciate the need for greater clarity. As FDA has communicated in previous notices, there are challenges in determining the precise number of respondents to the various information collection tasks, as well as in determining what specific activities are subject to review and approval by OMB under the PRA. Some activities may be considered usual and customary (5 CFR 1320.3(b)(2)) and therefore not subject to such review and approval. For this reason we have retained our currently approved estimates, but continue to consider public comment regarding the number of potential respondents to the collection activities as well as the corresponding annualized burden.

We estimate the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN[1]

Information collection activity in Sections 503a and 503b of the FD&C Act	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
503B AERs	55	1	55	1.10	61
503B Recordkeeping AERs	55	1	55	16	880
503A Reporting	45	~197	8,879	0.87	7,968
503A Recordkeeping	45	2	90	1	90
503A Disclosure (MOU)	1	1	1	1	1
Outsourcing facility reporting under 503B(b)	75	~108	8,111	0.2	214
Total			17,191		9,214

[1] There are no capital costs or operating and maintenance costs associated with this collection of information.

While we have retained our currently approved burden estimates, we have corrected an inadvertent omission from our 60-day notice in row 6 of Table 1 reflecting the number of estimated responses and average burden per response.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–03448 Filed 2–20–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Advancing Translational Sciences; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a

meeting of the National Center for Advancing Translational Sciences Advisory Council.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Advancing Translational Sciences Advisory Council.

Date: March 24, 2026.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Center for Advancing Translational Sciences, National Institutes of Health, 9609 Medical Center Drive, Room 1E454, Rockville, MD 20850.

Meeting Format: Virtual Meeting.

Contact Person: Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, National Institutes of Health, 9609 Medical Center Drive, Room 1E454, Rockville, MD 20850, (301) 435–0809, *anna.ramseyewing@nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Dated: February 18, 2026.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–03461 Filed 2–20–26; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–7107–N–01 OMB Control No.: 2506–0171]

30-Day Notice of Proposed Information Collection: HOME Investment Partnership

AGENCY: Office of Policy Development and Research, Chief Data Officer, HUD.

ACTION: Notice.

SUMMARY: HUD is seeking approval from the Office of Management and Budget (OMB) for the information collection described below. In accordance with the Paperwork Reduction Act, HUD is requesting comments from all interested parties on the proposed collection of information. The purpose of this notice is to allow for 30 days of public comment.

DATES: *Comments Due Date:* March 25, 2026.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function.

FOR FURTHER INFORMATION CONTACT: John L. Murphy, PRA Compliance Officer, Paperwork Reduction Act Division, PRAD, Department of Housing and Urban Development, 451 7th Street SW, Room 8220, Washington, DC 20410; email at *PaperworkReductionActOffice@hud.gov,* ATTN: John L. Murphy telephone (202) 402–8084. This is not a toll-free number. HUD welcomes and is prepared to receive calls from individuals who are deaf or hard of hearing, as well as individuals with speech or communication disabilities. To learn more about how to make an accessible telephone call, please visit *https://www.fcc.gov/consumers/guides/telecommunications-relay-service-trs.*

Copies of available documents submitted to OMB may be obtained from Dr. John L. Murphy.

SUPPLEMENTARY INFORMATION: This notice informs the public that HUD is seeking approval from OMB for the information collection described in Section A. The **Federal Register** notice that solicited public comment on the information collection for a period of 60 days was published on May 30, 2025 at 90 FR 23063.

A. Overview of Information Collection

Title of Information Collection: HOME Investment Partnerships Program.

OMB Approval Number: 2506–0171.

Type of Request: Reinstatement of Approved Collection.

Form Number: HUD Form 27055.

Description of the need for the information and proposed use: The information collected through HUD's Integrated Disbursement and Information System (IDIS) (24 CFR 92.502) is used by HUD Field Offices, HUD Headquarters, and HOME Program Participating Jurisdictions (PJs). The information on program funds committed and disbursed is used by HUD to track PJ performance and to determine compliance with HOME regulations. The project-specific property, tenant, owner, and financial data is used to compile annual reports to Congress required at Section 284(b) of the HOME Investment Partnerships Act, as well as to make program management decisions about how well program participants are achieving the statutory objectives of the HOME Program. Program management reports are generated by IDIS to provide data on the status of program participants' commitment and disbursement of HOME funds. These reports are provided to HUD staff as well as to HOME PJs. Management reports required in conjunction with the Annual Performance Report (§ 92.509) are used by HUD Field Offices to assess the effectiveness of locally designed programs in meeting specific statutory requirements and by Headquarters in preparing the Annual Report to Congress. Specifically, these reports permit HUD to determine compliance with the requirement that PJs provide a 25 percent match for HOME funds expended during the Federal fiscal year (Section 220 of the Act) and that program income be used for HOME eligible activities (Section 219 of the Act), as well as the Women and Minority Business Enterprise requirements (§ 92.351(b)). Financial, project, tenant and owner documentation is used to determine compliance with HOME Program cost limits (Section 212(e) of the Act), eligible activities (§ 92.205), and eligible costs (§ 92.206), as well as to determine whether program participants are achieving the income targeting and affordability requirements of the Act (Sections 214 and 215). Other information collected under Subpart H (Other Federal Requirements) is primarily intended for local program management and is only viewed by HUD during routine monitoring visits. The written agreement with the owner for long-term obligation (§ 92.504) and tenant protections (§ 92.253) are required to ensure that the property owner complies with these important elements of the HOME Program and are also reviewed by HUD during monitoring visits. HUD reviews all other data collection requirements during monitoring to assure compliance with the requirements of the Act and other related laws and authorities. HUD tracks PJ performance and compliance with the requirements of 24 CFR parts 91 and 92. PJs use the required information in the execution of their program, and to gauge their own performance in relation to stated goals.